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D-4F Does Not Mitigate
Key Parameters in Rat Model of
Severe Pulmonary Hypertension
R. Molthcn, S. Baumgardt, and K.A. Pritchard Jr.
Departmelll of Veterans Affairs, 'ltlblocki VAMC and
Medical College of Wisconsin, Milwaukee. USA

Summary
We e mpl oyed a new ly developed rat model of severe pulmonary hypertensio n (PH ) to stud y if treatment with apolipoprotein (apo)- mimeti c peptide, D4F, mitigates PH a nd re lated path o logy. Sprag ue-Daw ley rats underwent surgery to parti all y li gate their left pulmonary artery, after 3-days th ey were
injected with monocrotaline (MeT) a nd the n rando ml y se lected to receive a
daily inj ec ti on of D-4F o r sa line. After 2 1-days of treatment the ani ma ls were
exa min ed with respect to iso lated lung hemody namic measureme nt s and Xray microfoca l a ng iography. T here was no significant difference in ri ght-toleft hea rt weight , c hange in body weight , pulmonary vascu lar resis tance (PVR),
or pulmonary micro-vasc ul ar density betwee n D-4F and saline treated ralS.

Introduction
Pulmo nary hypertension results in remodeling of large and sma ll pulmonary vesse ls, a disturbance in the delicate balance of venti lati on/perfusion,
and increased load on the right heart. In late slages of the disease, severe PH
is accompanied by plexifo rm and neoi ntimal les ions which sig nifi ca ntl y inc rease pu lmonary vascular res ista nce I. '. A we ll accepted rat mode l of PH
in vo lves a si ngle subcutaneous injection of MeT, however, thi s model does
not resu It in neoi ntimal lesions. T he refo re, we have developed a rat mode l of
severe PH that com bines parti al li ga ti on of the left pulmonary art ery w ilh
MeT inj ecti o n resulting in the formation of neointimal lesions wh ich more
close ly mimi cs severe PH in hum an" The model is inherentl y useful for

©2007 by MEDIMOND S.r.I .

H815C0161

209

210

8th World Congress for Microcirculation

investigating possible anti-remodeling treatments aimed at reducing ce llul ar
pro life ration and, in turn, lowering pulmonary vascu lar resistance.
Apolipoprotein (a po) A-I and apoA-I-mimetic peptides hold great promise
for treatment of atherosclerosis" '. D-4F has been shown to significant ly reduce rapidly evolving atherosclerotic lesions , oxidation and innammation;
and, there is evidence that it has the ability to improve endothelia l function "'
'. For these reasons, D-4F was thought to be a good candidate for treatment
of vascular remode ling in this proliferative model, in which histology also
confirmed marked innammatory infiltrates'.

Materials and Methods
All the studies were done under approval of the Zablocki VA Medical
Center IACUC review board and in compliance with the National Research
Council's Guide for the Care and Use of Laboratory Animals. Fifteen (15)
mal e Sp rague-Daw ley rats (280-350 gm) und erwent a recovery surgery in
which the rat is anesthetized, intubated, then through thoracotomy the left
pulmonary artery is isolated, looped with 4-0 s uture and reduced s uch that the
ou ter vesse l diameter was 0.61 mm. The animals were allowed to recover for
3-days, then injected with MCT (60 mg/kg, sub-Q), and randomly selected to
receive an injection of either D-4F (I mg/ kg/day, i.p.) (N=8), or an equal
vo lume of saline (co ntrol C, N=7 ). Twenty-o ne (21) days after injections. the
animals were anesthetized, a cardiac blood sample drawn , the main pulmonary artery and trachea cannulated, and the heart and lungs excised. The right
ventricle was dissected from the heart and both segments weighed separately
as a measure of right ventricular hypertrophy . The iso lated intact lung was
prepared as previously described"" Brieny, the lun g was ventilated, rinse of
blood and perfused with a physiologic sa line so lution . Then the airway pressure held co nstant at 6 mmHg, the pulmonary vein pressure (Ppv) kept ambient. and pulmonary arterial (I' PAl pressure measured over a range of now rates
(Q, 0-40 ml/min). Finally, the perfusate was replaced with a vascular X-ray
con trast medium and microfocal angiography pelformed. All statistical comparisons were peJformed usi ng at-test (Pd"0.02) SigmaStat 3.0 (S PSS , Chicago, IL).

Results
There was no significant difference in key structure/function parameters of
the PH model between the D-4 F treated and the control rats. No significant
change was detected in the right ventricular hypertrophy , as meas ured by the
ratio of the weight of the ri g ht ventricle compared to the left ventricle plus
septum, see Figure I. There was no significant difference in the gain in body
weight over the 24-day experiment, see Figure 2. Treatment with D-4F did
not res ult in a sign ificant decrease in pulmonary vascular resistance, (PPA P,,)/Q,()(), where Q ,oo indicates now rate was normalized to body weight at 100
ml/min/kg, see Figure 3. Microfocal X-ray angiography did not detect any
difference in the pulmonary microvascular density, which is significantly reduced
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Fig ure I . Ratio of the weight of th e righl ventricle compa red (a {he left ventricle plus seplllm.
as a m easure 0/ right ventricular hypertrophy.

in MeT models of PH ', as shown in Figure 4. Interestingly , 2 of the rats that
were receiving OAF treatment di ed approximately 17 day s into the experiment (none o f the control rats died) and 0 -4F treated rats appeared to have
more labored breathing and their lun gs appeared worse compared to no ntreated PH rats o n gross assess me nt.

Conclusion
Treatment with OAF was not shown to miti gate measures of stru ctura l o r
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Figure 2. Gain in body weight over the 24-days of exper;melll.
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FiKure 3. Pulmona ry vascular resistance at a flow rate oJ 100 mllminlkg.
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Figure 4. Example high~magnificalion X-ray 011g;08'-01ll,\' of lower /ullg lobe in control Gild
D -4F Ireared rats. Inrravascular pres,mre is sel to 21 mmHg and airway pressure 6 mml-Ig.
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functional injury induced by a mode l of severe PH. For some animals it may
have exacerbated this experimenta ll y- induced illness and/or the progress ion
o f th e disease model. 0-4F has been shown to be highly effective at improv ing e nd othelial cell function, which may playa role in reducing rapid evolving vasc ular les ions and oxidative injury in experimentally-induced atherosc le ros is. MeT is known to be an endothelia l cell toxin , however, knowledge
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of the role and amount o f ox id ative stress in the M eT m ode l i s limited 'O One
possibility i s that D -4F m ay accelerate vascul ar occ lu si ve lesio ns in thi s model
of seve re PH by protecting endothe lial ce ll s from apoptotic cell death. D -4 F
may rescue endothelial ce ll s that sl o ug hed off of the vesse l wall , allow in g
them to remain in c ircu l ati on lo nger than normal and providing th em great er
opportunity to beco m e trapped in the lung and subseq ue ntl y comp licate and
accelerate vasc ulopath y in the mi crovascu lature of this model of PH . Supported by Department of Veterans Affairs.
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